Prospective investigation of risk factors for gastrointestinal adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer: A Gynecologic Oncology Group study

Journal article

Peer reviewed

R. Burger, M. Brady, M. Bookman, B. Monk, J. Walker, H. Homesley, J. Fowler, B. Greer, M. Boente and S. Liang

Gynecologic oncology, Vol.120, pp.S5-S5

03/01/2011

Metrics

5 Record Views

Title: Prospective investigation of risk factors for gastrointestinal adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer: A Gynecologic Oncology Group study
Creators: R. Burger - Fox Chase Cancer Center
M. Brady - NRG Oncology
M. Bookman - Arizona Oncology
B. Monk - Creighton University
J. Walker - Oklahoma City University
H. Homesley - Wake Forest University
J. Fowler - The Ohio State University
B. Greer - University of Washington Medical Center
M. Boente - Minnesota Oncology
S. Liang - North Shore University Hospital
Publication Details: Gynecologic oncology, Vol.120, pp.S5-S5
Publisher: Elsevier Inc
Identifiers: 991005968881502656
Academic Unit: Obstetrics & Gynecology
Language: English
Resource Type: Journal article